SFA Therapeutics vs Ankr
Side-by-side comparison of AI visibility scores, market position, and capabilities
Oral Treg modulator biotech with positive Phase 1b psoriasis safety data; $9.13M raised from Savantus Ventures competing in autoimmune therapy with a restore-immune-balance mechanism.
About
SFA Therapeutics is a Philadelphia-based clinical-stage biotech developing oral small molecule drugs that modulate regulatory T cells (Tregs) — the immune system's natural suppressor cells — to restore immune homeostasis in autoimmune diseases and cancer without the broad immunosuppression that existing biologics and small molecule therapies cause. The company raised $9.13 million from investors including Savantus Ventures and Ben Franklin Technology Partners, announced positive Phase 1b safety data for SFA-002 in psoriasis in March 2025, and received a 2025 Prix Galien USA Best Startup award nomination.
Decentralized Web3 infrastructure with RPC node access across 30+ blockchains; globally distributed nodes reduce latency; premium dedicated nodes for apps needing guaranteed throughput.
About
Ankr is a Web3 infrastructure platform offering remote procedure call node access to more than 30 blockchain networks through a globally distributed network of nodes run by independent operators. Unlike centralized providers that operate their own data centers exclusively, Ankr's decentralized architecture routes requests across geographically distributed nodes, improving latency for users in regions underserved by US- or EU-centric infrastructure. Its public free-tier RPC endpoints — available for Ethereum, BNB Chain, Polygon, Avalanche, Fantom, and dozens of others — have made Ankr one of the most widely used infrastructure providers in the multi-chain developer ecosystem.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.